Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2015 · 10-Q
Revenue$31.85M$31.85M+118.1% vs Q3 2014 Net Income-$28.95M-$28.95MN/M vs Q3 2014 EPS Diluted-$0.19-$0.19N/M vs Q3 2014 Gross Profit$4,197,000−6.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,985,000N/M Free Cash Flowderived-$17,321,000N/M Margins · derivedGross margin13.2%−17.5 pt vs Q3 2014
Operating margin-73.0%+57.3 pt vs Q3 2014
Net margin-90.9%+48.0 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end